Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17208431 | 0.92 | CHRM4 (0.52) | CHRM4DRD2USP30HTR2CCCR2 | |
| SCHEMBL15840435 | 0.86 | ALDH1A1 (0.53) | CHRM4DRD2ALDH1A1LMNARAB9A | |
| SCHEMBL15840442 | 0.85 | NPC1 (0.48) | KMT2AALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL15840444 | 0.83 | ADAMTS5 (0.57) | CHRM4NPC1 | |
| SCHEMBL30305344 | 0.83 | ADAM17 (0.45) | ADAM17 | |
| SCHEMBL20744367 | 0.83 | ADAM17 (0.45) | ADAM17 | |
| SCHEMBL15840485 | 0.82 | DRD2 (0.54) | CHRM4DRD2HTR2CKMT2A | |
| SCHEMBL15840453 | 0.82 | ADAMTS5 (0.56) | — | |
| SCHEMBL27382202 | 0.82 | DRD2 (0.57) | CHRM4DRD2USP30HTR2CCCR2 | |
| Hydrochloric Acid SCHEMBL11816492 | 0.82 | DRD2 (0.61) | CHRM4DRD2USP30HTR2CCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957249-B2 | Saturated nitrogen and N-acylated heterocycles potentiating the activity of an active antibiotic against Mycobacteria | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2018-05-01 | — | — | US | disclosed |
| US-9957249-B2 | Saturated nitrogen and N-acylated heterocycles potentiating the activity of an active antibiotic against Mycobacteria | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2018-05-01 | — | — | US | disclosed |
| US-20150307471-A1 | Saturated Nitrogen and N-Acylated Heterocycles Potentiating the Activity of an Active Antibiotic against Mycobacteria | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20150307471-A1 | Saturated Nitrogen and N-Acylated Heterocycles Potentiating the Activity of an Active Antibiotic against Mycobacteria | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2015-10-29 | — | — | US | disclosed |
| WO-2014096378-A1 | SATURATED NITROGEN AND N-ACYLATED HETEROCYCLES POTENTIATING THE ACTIVITY OF AN ACTIVE ANTIBIOTIC AGAINST MYCOBACTERIA | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307471-A1 | Saturated Nitrogen and N-Acylated Heterocycles Potentiating the Activity of an Active Antibiotic against Mycobacteria | NAT1, NAA15, FNTB | CHRM4 1668/4885DRD2 1356/4885USP30 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.